What we don't learn from clinical trials in epilepsy

Area of Science:

• Clinical Neurology
• Pharmacology
• Medical Research Methodology

Background:

• Randomized, double-blind trials are the gold standard for evaluating antiepileptic treatments.
• Translating trial findings into clinical practice faces challenges due to scientific rigor versus clinical relevance.
• Inaccurate self-reported seizure data and adverse events complicate trial interpretation.

Purpose of the Study:

• To explore the utility of patient preference as a valid outcome measure in antiepileptic drug trials.
• To address the limitations of traditional efficacy and safety endpoints.
• To enhance the clinical relevance and generalizability of trial results.

Main Methods:

• Review of existing literature on clinical trial design and outcome measures in epilepsy.
• Analysis of the potential of patient preference as a composite endpoint.
• Discussion of methodological considerations for incorporating patient-reported outcomes.

Main Results:

• Patient preference can serve as a feasible outcome measure in clinical trials.
• This approach inherently integrates treatment efficacy and tolerability.
• It offers a patient-centered validation of therapeutic interventions.

Conclusions:

• Patient preference provides a valuable, patient-oriented endpoint for antiepileptic drug trials.
• Incorporating patient preference can improve the clinical applicability of research findings.
• This outcome measure addresses the limitations of relying solely on objective seizure counts and adverse event reporting.